Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sawai and T’s Pharma Won Forxiga Generics by Skirting Patent, Will the Strategy Hold?
September 11, 2025
- Welireg Expected to Preserve Organ Function in VHL Disease: Urologist
September 11, 2025
- Sobi Japan Targets Five Rare Diseases in Five Years, Says President
September 10, 2025
- Teijin Pharma Bets on Ascendis Rare Disease Assets as Feburic Sales Crumble
September 10, 2025
- Gilead Says It Has No Intention to Scrap License Deal: Carna Bio
September 10, 2025
- Teikoku to Take Over Janssen’s Lopemin in Japan
September 10, 2025
- Nippon Shinyaku’s EGPA Drug Bags Fast-Track Status in US
September 10, 2025
- Lilly Japan Ramps Up Seishin Plant with New Building and Packaging Line
September 9, 2025
- Janssen Files TAR-200 in Japan for High-Risk Bladder Cancer
September 9, 2025
- Amicus CEO Confident on US$1 Billion Sales Target as Japan Pompe Launch Gets Underway
September 9, 2025
- GSK Recalls 7 Lots of Omjjara in Japan over Quality Issue
September 9, 2025
- Takeda Nabs Label Expansion for VWD Drug Vonvendi in US
September 9, 2025
- Talvey Seen as Promising Option for Hard-to-Treat Multiple Myeloma: Oncologist
September 8, 2025
- KM Biologics Developing Higher-Yield Liquid Immunoglobulin to Boost Efficiency and Supply
September 8, 2025
- Susmed Wins Partial Change Approval for Insomnia App, Seeks Coverage
September 8, 2025
- Ferring Files for Japan Approval of Bladder Cancer Gene Therapy
September 8, 2025
- Kaken’s Onychomycosis Drug Grabs German Approval
September 8, 2025
- Japan Ethical Drug Sales Inch Up 0.7% in July: Crecon
September 8, 2025
- Nichi-Iko Shows Signs of Recovery but Restructuring Still Underway: CEO
September 5, 2025
- And Pharma Chief Pledges Growth Strategy as New Generics Holding Firm Takes Shape
September 5, 2025
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…